About Encruso

Nano Therapeutics is the first company in India to develop and launch Everolimus Eluting Coronary Stent System (Encruso)<br /> Encruso, offers a stent with unmatched surface finish. With its ultra-thin strut thickness, Encruso stent provides increased flexibility, reduced profile, improved trackability, and faster endothelialization, while its high resistance against arterial pressure and radial force ensures no structural deformation during overexpansion.